Luxeptinib Preclinical Data Extend Potential Applications from Oncology to Inflammation
02 mai 2022 16h10 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 02, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Reports Results for the Third Quarter 2020
10 nov. 2020 16h01 HE
|
Aptose Biosciences, Inc.
Dosing Initiated in CG-806 Phase 1 a/b Study in AML Patients at 450mg Dose Level Nodal Reductions Observed and Dosing Continues in CG-806 Phase 1 a/b Study in CLL Patients Dosing Continues in...
Aptose to Present CG-806 and APTO-253 Data at the 2020 ASH Annual Meeting
04 nov. 2020 10h17 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...
Aptose Initiates Dosing of CG-806 in Patients with Acute Myeloid Leukemia
19 oct. 2020 07h00 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated...
Aptose Announces FDA Allowance of IND for Phase 1a/b Study of CG-806 in Acute Myeloid Leukemia
29 juin 2020 07h01 HE
|
Aptose Biosciences, Inc.
Oral FLT3/BTK inhibitor CG-806 expands development beyond B-cell malignancies to the treatment of AML Phase 1a/b study in B-cell malignancies continues through dose escalation SAN DIEGO and TORONTO,...
Aptose Presents New Preclinical CG-806 Data at the 2019 ASH Annual Meeting
09 déc. 2019 11h00 HE
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...
Aptose Reports Results for the Second Quarter Ended June 30, 2019
06 août 2019 16h00 HE
|
Aptose Biosciences, Inc.
─ APTO-253 Inhibits MYC in AML and MDS Patients in Phase 1 Clinical Trial ─ ─ First CLL Patient Dosed with CG-806 in Phase 1 Clinical Trial ─ Conference Call and Webcast at 5pm EDT Today ...
Aptose Doses First CLL Patient in Phase 1 Study of CG-806 and Doses Third Cohort in Phase 1 Study of APTO-253
16 juil. 2019 07h05 HE
|
Aptose Biosciences, Inc.
– CG-806 oral non-covalent pan-FLT3/pan-BTK inhibitor being developed for the treatment of CLL and other B-cell malignancies and for AML – – APTO-253 MYC inhibitor being developed for the...
Aptose Reports Results for the First Quarter Ended March 31, 2019
07 mai 2019 16h01 HE
|
Aptose Biosciences, Inc.
─ Patient Dosed at Second Dose Level in APTO-253 Clinical Trial ─ ─ Patient Screening Initiated for CG-806 Clinical Trial ─ Conference Call and Webcast at 5pm EDT Today SAN DIEGO and TORONTO, May...
Aptose Announces FDA Allowance of Investigational New Drug Application for CG-806
25 mars 2019 07h02 HE
|
Aptose Biosciences, Inc.
– CG-806 highly potent, oral, non-covalent pan-FLT3/pan-BTK inhibitor being developed for the treatment of CLL and other B-cell malignancies and for AML – – Phase 1 trial in relapsed or refractory...